|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **ER = 0%****(N=94)** | **ER = 1-79%****(N=42)** | **ER >= 80%****(N=275)** | **p-value** | **PR = 0%****(N=135)** | **PR = 1-79%****(N=119)** | **PR >= 80%****(N=157)** | **p-value** |
| **Age** | Median (Range) | 56.8 (19.8-88.1) | 53.16 (32.2-81.2) | 59.7(31.8-86.2) | **0.004** | 58.0 (19.8-88.1) | 56.2 (32.2-85.6) | 59.4(31.8-86.2) | 0.353 |
| **Sex** | Female  | 94 (100%)  | 42 (100%) | 275 (100%) | **-** | 135 (100%)  | 119 (100%) | 157 (100%) | - |
| **Year of diagnosis****(median)** |   | 2014  | 2012 | 2014 | **<0.001** | 2014  | 2014 | 2014 | 0.277 |
| **Follow up** | Median (Mean) | 35.9 (43.9)  | 46.4 (61.2)  | 36.1 (41.6) | **<0.001** | 35.2 (41.5)  | 41.7 (49.5)  | 36.6 (42.2) | 0.073 |
| **Histology** |   |   |   |  | **0.014** |   |   |  | 0.356 |
|  | Unknown | 1 (1.1%) | 0 (0.0%) | 1 (0.0%) |  | 118 (87.4%) | 98 (82.4%) | 134 (85.4%) |  |
|  | Invasive Ductal Carcinoma | 86 (91.5%) | 39 (92.9%) | 225 (81.8%) |  | 10 (7.4%) | 18 (15.1%) | 20 (12.7%) |  |
|  | Invasive Lobular Carcinoma | 2 (2.1%) | 3 (7.1%) | 43 (15.6%) |  | 1 (0.7%) | 1 (0.8%) | 0 (0.0%) |  |
|  | Inflammatory | 1 (1.1%) | 0 (0.0%) | 1 (0.4%) |  | 2 (1.5%) | 0 (0.0%) | 0 (0.0%) |  |
|  | Metaplastic Carcinoma | 2 (2.1%) | 0 (0.0%) | 0 (0.0%) |  | 3 (2.2%) | 1 (0.8%) | 3 (1.9%) |  |
|  | Mixed | 2 (2.1%) | 0 (0.0%) | 5 (1.8%) |  | 1 (0.7%) | 1 (0.8%) | 0 (0.0%) |  |
| **Grade** |   |   |   |  | **<0.0001** |   |   |  | <**0.0001** |
|  | I | 0 (0.0%) | 6 (14.3%) | 77 (28.0%) |  | 7 (5.2%) | 22 (18.5%) | 54 (34.4%) |  |
|  | II | 14 (14.9%) | 14 (33.3%) | 126 (45.8%) |  | 34 (25.2%) | 46 (38.7%) | 74 (47.1%) |  |
|  | III | 78 (83.0%) | 22 (52.4%) | 68 (24.7%) |  | 91 (67.4%) | 48 (40.3%) | 29 (18.5%) |  |
|  | Unknown | 2 (2.1%) | 0 (0.0%) | 4 (1.5%) |  | 3 (2.2%) | 3 (2.5%) | 0 (0.0%) |  |
| **T-Stage** |   |   |   |  | **0.018** |   |   |  | **0.007** |
|  | T0 | 2 (2.1%) | 0 (0.0%) | 0 (0.0%) |  | 2 (1.5%) | 0 (0.0%) | 0 (0.0%) |  |
|  | T1a | 7 (7.4%) | 2 (4.8%) | 23 (8.4%) |  | 10 (7.4%) | 8 (6.7%) | 14 (8.9%) |  |
|  | T1b | 7 (7.4%) | 6 (14.3%) | 52 (18.9%) |  | 12 (8.9%) | 16 (13.4%) | 37 (23.6%) |  |
|  | T1c | 27 (28.7%) | 8 (19.0%) | 92 (33.5%) |  | 44 (32.6%) | 34 (28.6%) | 49 (31.2%) |  |
|  | T2 | 33 (35.1%) | 17 (40.5%) | 82 (29.8%) |  | 45 (33.3%) | 40 (33.6%) | 47 (29.9%) |  |
|  | T3 | 13 (13.8%) | 8 (19.0%) | 20 (7.3%) |  | 18 (13.3%) | 14 (11.8%) | 9 (5.7%) |  |
|  | T4 | 1 (1.1%) | 0 (0.0%) | 0 (0.0%) |  | 1 (0.7%) | 0 (0.0%) | 0 (0.0%) |  |
|  | T4b | 0 (0.0%) | 1 (2.4%) | 2 (0.7%) |  | 0 (0.0%) | 3 (2.5%) | 0 (0.0%) |  |
|  | T4c | 0 (0.0%) | 0 (0.0%) | 1 (0.4%) |  | 0 (0.0%) | 1 (0.8%) | 0 (0.0%) |  |
|  | T4d | 3 (3.2%) | 0 (0.0%) | 2 (0.7%) |  | 3 (2.2%) | 1 (0.8%) | 1 (0.6%) |  |
|  | Unknown | 1 (1.1%) | 0 (0.0%) | 1 (0.4%) |  | 0 (0.0%) | 2 (1.7%) | 0 (0.0%) |  |
| **Overall Stage** |   |   |   |  | 0.068 |  |  |  | 0.168 |
|  | I | 37 (39.4%) | 13 (31.0%) | 134 (48.7%) |  | 54 (40.0%) | 50 (42.0%) | 80 (51.0%) |  |
|  | II | 36 (38.3%) | 19 (45.2%) | 104 (37.8%) |  | 55 (40.7%) | 45 (37.8%) | 59 (37.6%)  |  |
|  | III | 21 (22.3%) | 10 (23.8%) | 37 (13.5%) |  | 26 (19.3%) | 24 (20.2%) | 18 (11.5%) |  |
| **SERM/AI** |  |  |  |  | **<0.0001** |  |  |  | **<0.0001** |
|  | Tx Given | 8 (8.5%) | 38 (90.5%) | 267 (97.1%) |  | 47 (34.8%) | 113 (95.0%) | 153 (97.5%) |  |
|  | No Tx | 86 (91.5%) | 4 (9.5%) | 5 (1.8%) |  | 88 (65.2%) | 4 (3.4%) | 3 (1.9%) |  |
|  | Unknown | 0 (0.0%) | 0 (0.0%) | 3 (1.1%) |  | 0 (0.0%) | 2 (1.7%) | 1 (0.6%) |  |

**Supplementary Table 1.** Demographics and tumor characteristics of breast cancer patients stratified by percentage ER and PR positivity.